Literature DB >> 16557288

A possible link between the pseudoexfoliation syndrome and coronary artery disease.

M Citirik1, G Acaroglu, C Batman, L Yildiran, O Zilelioglu.   

Abstract

PURPOSE: This is a collaborative case-control study from Ophthalmology and Cardiology departments of a tertiary care hospital, designed to explore the relationship between coronary artery disease (CAD) and pseudoexfoliation syndrome (PEX).
METHOD: In all, 50 patients with CAD proven by coronary angiography, and 50 controls with normal coronary angiographic findings were compared in terms of PEX, other vascular diseases, and retinal vascular findings. chi2-test and Student's t-test were used for statistical analysis.
RESULTS: The number of patients with PEX among CAD (+) patients was substantially larger than controls. In all, 28 of 50 CAD (+) patients and only 12 of 50 CAD (-) patients had PEX. PEX was significantly associated with CAD (P=0.001). When all patients were regrouped according to the presence of PEX, patients with PEX did not differ from patients without PEX in terms of age (P=0.360) and sex (P=0.507), but the prevalence of CAD was higher (P=0.001) and fundoscopic findings of vascular diseases were significantly more prominent (P=0.0001) in PEX (+) patients. DISCUSSION: We demonstrated statistically significant difference in the prevalence of PEX in CAD patients, and also in the prevalence of CAD in PEX (+) individuals. These were striking differences. We should consider the possibility of the presence of PEX in CAD patients; and the predisposition of PEX (+) persons for CAD, which necessitates a fundus examination for findings of systemic vascular diseases.

Entities:  

Mesh:

Year:  2006        PMID: 16557288     DOI: 10.1038/sj.eye.6702177

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  22 in total

Review 1.  The medical and surgical management of pseudoexfoliation glaucoma.

Authors:  Manishi A Desai; Richard K Lee
Journal:  Int Ophthalmol Clin       Date:  2008

Review 2.  [PEX syndrome. Clinical diagnosis and systemic manifestations].

Authors:  E Scharfenberg; U Schlötzer-Schrehardt
Journal:  Ophthalmologe       Date:  2012-10       Impact factor: 1.059

3.  Pseudoexfoliation syndrome and coronary artery ectasia.

Authors:  M O Akdemir; M R Sayin; M Armut; I Akpinar; S H Ugurbas
Journal:  Eye (Lond)       Date:  2014-03-07       Impact factor: 3.775

4.  Assessment of myocardial ischaemia using tissue Doppler imaging in pseudoexfoliation syndrome.

Authors:  N Demir; T Ulus; O E Yucel; E T Kumral; E Singar; H I Tanboga
Journal:  Eye (Lond)       Date:  2011-06-24       Impact factor: 3.775

5.  Aqueous humor and serum erythropoietin levels in patients with pseudoexfoliation syndrome and pseudoexfoliative glaucoma.

Authors:  Başak Doğu; Nurşen Yüksel; Mustafa Baki Cekmen; Yusuf Cağlar
Journal:  Int Ophthalmol       Date:  2010-09-23       Impact factor: 2.031

6.  Plasma adropin level in patients with pseudoexfoliation.

Authors:  Tevfik Oğurel; Reyhan Oğurel; Mustafa Topuz; Nurgül Örnek; Kemal Örnek
Journal:  Int Ophthalmol       Date:  2016-02-10       Impact factor: 2.031

7.  Association of ocular pseudoexfoliation syndrome with ischaemic heart disease, arterial hypertension and diabetes mellitus.

Authors:  Martynas Spečkauskas; Abdonas Tamošiūnas; Vytautas Jašinskas
Journal:  Acta Ophthalmol       Date:  2012-05-02       Impact factor: 3.761

8.  Atherogenic indices in pseudoexfoliation syndrome.

Authors:  Enver Mirza
Journal:  Eye (Lond)       Date:  2019-07-05       Impact factor: 3.775

9.  The evaluation of vestibular functions in patients with pseudoexfoliation syndrome.

Authors:  Burak Turgut; Hayrettin Cengiz Alpay; Mehmet Kaan Kaya; Muzaffer Oger; Ulku Celiker; Sinasi Yalcin
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-09-16       Impact factor: 2.503

10.  Link of ocular pseudoexfoliation syndrome and vascular system changes: results from 10-year follow-up study.

Authors:  Ugnė Rumelaitienė; Dalia Žaliūnienė; Martynas Špečkauskas; Abdonas Tamošiūnas; Ričardas Radišauskas; Emilija Jusevičiūtė; Vidas Vainauskas; Gailutė Bernotienė
Journal:  Int Ophthalmol       Date:  2020-01-19       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.